natgillin/translations-raw huggingface dataset:
Leukocytose (leukocyttal > 50 x 109/l) observeredes hos 41 % af donorer, og forbigående trombocytopeni (trombocyttal < 100 x 109/l) efter filgrastim og leukaferese observeredes hos 35 % af donorerne.
Leukocytosis (WBC > 50 x 109/l) was observed in 41% of donors and transient thrombocytopenia (platelets < 100 x 109/l) following filgrastim and leukapheresis was observed in 35% of donors.
Leukocytose blev observeret hos donorer og thrombocytopeni efter filgrastim, og leukaferese blev ligeledes observeret hos donorerne.
Leukocytosis was observed in donors andthrombocytopenia following filgrastim and leukapheresis was also observed in donors.
Leukocytose blev observeret hos donorer, lige som der også blev set trombocytopeni efter filgrastim og leukaferese.
Leukocytosis was observed in donors and thrombocytopenia following filgrastim and leukapheresis was also observed in donors.
Leukocytose blev observeret hos donorerne og trombocytopeni efter filgrastim og leukaferese blev også observeret hos donorerne.
Leukocytosis was observed in donors and thrombocytopenia following filgrastim and leukapheresis was also observed in donors.
Leukocytose optrådte hos 50% af patienter med APL vurderet ud fra en hæmatologisk bedømmelse.
Leukocytosis occurred in 50% of patients with APL, as determined by haematology assessments.
leukocytose trombocytopeni idiopatisk trombocytopenisk purpura pancytopeni
idiopathic thrombocytopaenic purpura
Leukocytose*, splenomegali*
Leukocytosis*, Splenomegaly
Leukocytose, lymfadenopati
Leukocytosis, Lymphadenopathy
leukocytose, trombocytopeni idiopatisk trombocytopenisk purpura pancytopeni
idiopathic thrombocytopaenic purpura
Leukocytosea
Leukocytosisa
Leukocytosea
Oropharyngeal paina
Leukocyttal (WBC) på 100 x 109/l eller højere er set hos mindre end 1% af patienter, behandlet med Neulasta.
White blood cell (WBC) counts of 100 x 109/l or greater have been observed in less than 1% of patients receiving Neulasta.
Leukocyttal (WBC) på 100 x 109/l eller højere er set hos mindre end 1% af patienter, behandlet med Ristempa.
White blood cell (WBC) counts of 100 x 109/l or greater have been observed in less than 1% of patients receiving Ristempa.
leukocyttal < 3.000/mm³
leukocyte count < 3000/mm³
Leukocyttallet bør dog kontrolleres regelmæssigt under filgrastimterapi på grund af den potentielle risiko, der er forbundet med svær leukocytose.
However, in view of the potential risks associated with severe leukocytosis, a white blood cell count should be performed at regular intervals during filgrastim therapy.
Leukocytter<10 x 109/l, trombocytter <450 x 109/l, myelocytter+metamyelocytter <5% i blod, ingen blaster og promyelocytter i blod, basofile <20%, ingen ekstramedullær påvirkning
WBC < 10 x 109/l, platelet < 450 x 109/l, myelocyte+metamyelocyte < 5% in blood, no blasts and promyelocytes in blood, basophils < 20%, no extramedullary involvement
Leukoencefalopa ti, anosmi
Leukoenceph- alopathy, anosmia
Leukoencefalopati, anosmi
Leukoenceph- alopathy, anosmia
leukopeni
leucopaenia
Leukopeni (2)
Leucopenia (2)
Leukopeni (27,9 %) (G3/4: 17,0 %)
Leukopenia (27.9%) (G3/4: 17.0%)
leukopeni (inklusive neutropeni og agranulocytose),
leucopaenia (including neutropaenia and
leukopeni (inklusive neutropeni og agranulocytose), anæmi
leucopaenia (including neutropaenia and
Leukopeni (leukopeni, nedsat antal hvide blodlegemer).
Leukopenia (Leukopenia, White blood cell count decreased).
Leukopeni er den hyppigst erfarede bivirkning af Caelyx i denne patientgruppe; neutropeni, anæmi og trombocytopeni er blevet observeret.
Leukopaenia is the most frequent undesirable effect experienced with Caelyx in this population; neutropaenia, anaemia and thrombocytopaenia have been observed.
Leukopeni Lymfopeni
Leukopenia
leukopeni neutropeni
leucopenia, neutropenia
Leukopeni Neutropenib
Leucopenia,
Leukopeni Trombocytopeni
Constipation
Leukopeni Trombocytopeni
Respiratory disorder
Leukopeni Trombocytopeni Febril neutropeni Anæmi Pancytopeni Granulocytopeni
Leukopenia Thrombocytopenia Febrile neutropenia Anaemia Pancytopenia Granulocytopenia
Leukopeni*
Leukopenia
Leukopeni**
Leukopaenia
Leukopeni**** Neutropeni**** Anæmi****
Leukopenia**** Neutropenia**** Anemia
Leukopeni*, lymfopeni*
Leukopenia*, Lymphopenia
Leukopeni*, trombocytopeni*, pancytopeni, agranulocytose
Leukopenia*, thrombocytopenia*, pancytopenia, agranulocytosis
leukopeni,
eosinophilia
leukopeni, anæmi
, leukopenia, anaemia
Leukopeni, anæmi
Leukopaenia, anaemia
Leukopeni, anæmi, trombocytopeni
Hypochromic anaemia
leukopeni, erytrocytabnormitet
Anaemia, leukopenia, red blood cell abnormality
Leukopeni, neutropeni
Leukopenia, Neutropenia
Leukopeni, neutropeni og agranulocytose
Leukopenia, neutropenia, and agranulocytosis
leukopeni, neutropeni, anæmi
leukopenia, neutropenia, anaemia
leukopeni, neutropeni, trombocytopeni
leukopenia, neutropenia, thrombocytopenia
Leukopeni, smerter i lymfeknuder
Leukopenia, lymph node pain
leukopeni, trombocytope- ni
leukopenia, thrombocytope- nia
leukopeni, trombocytopeni
Leucopenia, thrombocytopenia
leukopeni, trombocytopeni
Leukopenia, thrombocytopenia
Leukopeni, trombocytopeni, allergiske reaktioner, hyperglykæmi, hypertoni, perifer neuropati, myokardieinfarkt, arytmi (herunder bradykardi, ventrikulær takykardi og atrieflimren), vaskulitis, pankreatitis, gastritis, gingival hyperplasi, hepatitis, gulsot, forhøjede leverenzymer*, angioødem, erythema multiforme, urticaria, eksfoliativ dermatitis, Stevens-Johnsons syndrom, quinckes ødem, lysfølsomhed.
Leukocytopenia, thrombocytopenia, allergic reactions, hyperglycaemia, hypertonia, peripheral neuropathy, myocardial infarction, arrhythmia (including bradycardia, ventricular tachycardia and atrial fibrillation), vasculitis, pancreatitis, gastritis, gingival hyperplasia, hepatitis, jaundice, hepatic enzymes increased*, angioedema, erythema multiforme, urticaria, exfoliative dermatitis, Stevens-Johnson syndrome, Quincke oedema, photosensitivity.
Leukopeni, trombocytopeni, anæmi
Leucopenia, thrombocytopenia, anaemia
Leukopeni, trombocytopeni, anæmi
Leukopenia, thrombocytopenia, anaemia
Leukopeni, trombocytopeni, anæmi og neutropeni (inkl. febril neutropeni) er blevet forbundet med nelarabin-behandling.
Leukopenia, thrombocytopenia, anaemia, and neutropenia, (including febrile neutropenia) have been associated with nelarabine therapy.
Leukopeni: Incidensen af leukopeni, der blev rapporteret som en bivirkning, var 4 % i gruppen, der fik Benlysta og 2 % i gruppen, der fik placebo.
Leucopenia: The incidence of leucopenia reported as an adverse event was 4% in the group receiving Benlysta and 2% in the group receiving placebo.
Leukopeni: Kliniske undersøgelser har meldt om leukopeni i forbindelse med bexaroten-terapi.
Leucopenia: leucopenia associated with bexarotene therapy has been reported in clinical studies.
Leukopenia
Leukopeniaa
Leukopeniam, trombocytopeniam
Leukopeniaam, thrombocytopeniaam
Leukopenic (15%)
Leukopeniac (15%)
LeukoScan (0,31 pulver til injektionsvæske, opløsning) (sulesomab)
LeukoScan (0.31 powder for solution for injection) (sulesomab)
LeukoScan 0,31 mg Pulver til injektionsvæske, opløsning sulesomab
LeukoScan 0.31 mg, powder for solution for injection sulesomab
LeukoScan 0,31 mg pulver til injektionsvæske, opløsning.
LeukoScan 0.31 mg, powder for solution for injection
LeukoScan anvendes til at bestemme lokalisering og udstrækning af infektion og inflammation (betændelse) hos patienter med formodet osteomyelitis (knogleinfektion), herunder patienter med diabetiske fodsår.
LeukoScan is used to find the site and extent of infection or inflammation in patients with suspected osteomyelitis (bone infection), including patients with diabetic foot ulcers.
LeukoScan er indiceret til billeddiagnostisk fremstilling med henblik på at lokalisere og bedømme omfanget af infektion/inflammation i knogler hos patienter med mulig osteomyelitis inklusive patienter med diabetisk fodsår.
LeukoScan is indicated for diagnostic imaging for determining the location and extent of infection/inflammation in bone in patients with suspected osteomyelitis, including patients with diabetic foot ulcers.
LeukoScan udseende og pakningstørrelse
What LeukoScan looks like and contents of the pack
Leukostasesyndrom
Leukostasis syndrome
leukæmi
leukaemia1)
Leukæmi (blodkræft).
leukaemia (cancer of the blood cells).
leukæmi (kræft som påvirker blod og knoglemarv)
leukaemia (cancer affecting the blood and bone marrow)
leukæmi (kræft som påvirker blod og knoglemarv);
leukaemia (cancer affecting the blood and bone marrow);
leukæmi (kræft som påvirker blod og knoglemarv);
leukemia (cancer affecting the blood and bone marrow);
Leukæmi (rapporteret hos et lille antal patienter med væksthormonmangel, hvoraf nogle er blevet behandlet med somatropin.
Leukaemia (This has been reported in a small number of growth hormone deficiency patients, some of whom have been treated with somatropin.
leukæmi1)
leukaemia1)
Leukæmi†
Leukaemia
Leuprorelin 3,75 mg/ måned N=93
3.75 mg/ month N=93
Levadopa øger mængden af dopamin og nedsætter herved symptomerne på Parkinsons sygdom.
Levodopa increases the amount of dopamine and hence reduces the symptoms of Parkinson’s disease.
Levemir 100 enheder/ml
Levemir 100 units/ml
Levemir 100 enheder/ml injektionsvæske, opløsning i cylinderampul
Levemir 100 units/ml solution for injection in cartridge
Levemir 100 enheder/ml injektionsvæske, opløsning i fyldt pen
Levemir 100 units/ml solution for injection in pre-filled pen
Levemir 100 enheder/ml, injektionsvæske, opløsning i cylinderampul.
Levemir 100 units/ml solution for injection in cartridge.
Levemir 100 enheder/ml, injektionsvæske, opløsning i fyldt pen.
Levemir 100 units/ml solution for injection in pre-filled pen.
Levemir aktivitetsprofiler hos patienter med type 1-diabetes.
Activity profiles of Levemir in patients with type 1 diabetes.
Levemir anvendes til at sænke det høje blodsukkerniveau hos voksne, unge og børn der er fyldt 1 år med sukkersyge (diabetes mellitus).
Levemir is used to reduce the high blood sugar level in adults, adolescents and children aged 1 year and above with diabetes mellitus (diabetes).
Levemir anvendes til at sænke det høje blodsukkerniveau hos voksne, unge og børn, der er fyldt 1 år med sukkersyge (diabetes mellitus).
Levemir is used to reduce the high blood sugar level in adults, adolescents and children aged 1 year and above with diabetes mellitus (diabetes).
Levemir blev givet som basalinsulin til 33% (N=147) af patienterne (heraf tog 97,3% metformin).
Levemir was the basal insulin product for 33% (N = 147) of the patients (97.3% using metformin).
Levemir blev undersøgt i et åbent, randomiseret, kontrolleret klinisk studie med gravide kvinder med type 1-diabetes (n=310) behandlet med et basalbolus-behandlingsregime med Levemir (n=152) eller NPH insulin (n=158) som basal-insulin, begge i kombination med NovoRapid (se punkt 4.6).
Levemir was studied in an open-label randomised controlled clinical trial pregnant women with type 1 diabetes (n=310) were treated in a basal-bolus treatment regimen with Levemir (n=152) or NPH insulin (n=158) as basal insulin, both in combination with NovoRapid (see section 4.6).
Levemir blev undersøgt i et åbent, randomiseret, kontrolleret klinisk studie med gravide kvinder med type 1-diabetes (n=310) behandlet med et basalbolus-behandlingsregime med Levemir (n=152) eller NPH-insulin (n=158) som basal-insulin, begge i kombination med NovoRapid (se punkt 4.6).
Levemir was studied in an open-label randomised controlled clinical trial pregnant women with type 1 diabetes (n=310) were treated in a basal-bolus treatment regimen with Levemir (n=152) or NPH insulin (n=158) as basal insulin, both in combination with NovoRapid (see section 4.6).
Levemir er stort set natriumfrit.
Levemir is essentially ‘sodium-free’.
Levemir FlexPen er en fyldt pen, beregnet til brug sammen med NovoFine eller NovoTwist engangsnåle med en længde på op til 8 mm.
Levemir FlexPen is a pre-filled pen designed to be used with NovoFine or NovoTwist disposable needles up to a length of 8 mm.
Levemir FlexPen er farvekodet og en indlægsseddel er vedlagt med detaljerede brugerinstruktioner, som skal følges.
Levemir FlexPen is colour-coded and accompanied by a package leaflet with detailed instructions for use to be followed.
Levemir FlexTouch er en fyldt pen, beregnet til brug sammen med NovoFine eller NovoTwist engangsnåle med en længde på op til 8 mm.
Levemir FlexTouch is a pre-filled pen designed to be used with NovoFine or NovoTwist disposable needles up to a length of 8 mm.
Levemir FlexTouch er farvekodet og en indlægsseddel er vedlagt med detaljerede brugerinstruktioner, som skal følges.
Levemir FlexTouch is colour-coded and accompanied by a package leaflet with detailed instructions for use to be followed.
Levemir indeholder mindre end 1 mmol natrium (23 mg) per dosis, dvs.
Levemir contains less than 1 mmol sodium (23 mg) per dose, i.e.
Levemir InnoLet er en fyldt pen, beregnet til anvendelse sammen med NovoFine eller NovoTwist engangsnåle med en længde på op til 8 mm.
Levemir InnoLet is a pre-filled pen designed to be used with NovoFine or NovoTwist disposable needles up to a length of 8 mm.
Levemir kan anvendes til unge og børn, der er fyldt 1 år.
Levemir can be used in adolescents and children aged 1 year and above.
Levemir kan anvendes til ældre patienter.
Levemir can be used in older patients.
Levemir var non-inferiørt sammenlignet med NPH insulin målt på HbA1c i gestationsuge (GW) 36 og med sammenlignelig reduktion i middel HbA1c gennem graviditeten, se tabel 4.
Levemir was non-inferior to NPH insulin as measured by HbA1c at gestational week (GW) 36, and the reduction in mean HbA1c through pregnancy was similar, see table 4.
Levemir én gang dagligt
Levemir once daily
Levende attenueret aviær infektiøs bronchitis virus (IBV), stammevariant 4-91:  3,6 log10 EID50 *
Live attenuated avian infectious bronchitis virus (IBV), variant strain 4-91:  3.6 log10 EID50
Levende attenueret aviær infektiøs bronchitis virus stammevariant 4-91:  3,6 log10 EID50 * per dosis
Live attenuated infectious bronchitis virus variant strain 4-91:  3.6 log10 EID50* per dose
Levende attenueret Infektiøs Bronchitis Virus stamme 4-91  3,6 log10 EID50 *per dosis
Live attenuated infectious bronchitis virus strain 4-91  3.6 log10 EID50* per dose
Levende attenueret parvovirus fra moskusand
Live attenuated Muscovy duck parvovirus.
Levende attenueret parvovirus fra moskusand stamme GM 199 ........................
Live attenuated Muscovy duck parvovirus strain GM 199 ......................
Levende attenueret parvovirus fra moskusand stamme GM 199 ........................
Live attenuated Muscovy duck parvovirus strain GM 199 ...............................
Levende attenueret parvovirus fra moskusand stamme GM 199 ........................
Live attenuated Muscovy duck parvovirus strain GM 199 ....................................
Levende deletions-mutant Streptococcus equi stamme TW928 109,0 til 109,4 cfu1
Live deletion mutant Streptococcus equi strain TW928 109.0 to 109.4 cfu1 1colony forming units
Levende E. coli: 5,2 x 106 til 9,1 x 108 CFU/dosis
Live E. coli: 5.2 x 106 to 9.1 x 108 CFU/dose
Levende E.coli, O8:K87.
Live E.coli, O8:K87.
Levende Escherichia coli hvor aroA-genet er fjernet, type O78 5,2 x 106 til 9,1 x 108 CFU/dosis
Live aroA gene deleted Escherichia coli, type O78 5.2 x 106 to 9.1 x 108 CFU/ds
Levende Felin Calicivirus (stamme F9)
Live feline calicivirus (strain F9) 104.6-106.1 CCID50
Levende Felin Panleucopeni virus (stamme LR 72)
Live feline panleucopenia virus (strain LR 72) 103.7
Levende fødte børn
Live birth
Levende gE- tk- dobbelt-gen deleteret Bovin Herpesvirus type 1 (BoHV-1), stamme CEDDEL: 106.3 –
Live gE- tk- double-gene deleted bovine herpes virus type 1 (BoHV-1), strain CEDDEL: 106.3 – 107.3 CCID50.
Levende myxoma vector RHD virus
Live myxoma vectored RHD virus.
Levende myxoma vector RHD virus stamme 009:  103.0 FFU/dosis
Live myxoma vectored RHD virus strain 009: 103.0 FFU/dose.
Levende myxoma vector RHD virus stamme 009:  103.0 og  106.1 FFU*
Live myxoma vectored RHD virus strain 009: 103.0 and 106.1 FFU
Levende rekombinant vaccine mod infektiøs bursal sygdom og Marek’s sygdom.
Live recombinant vaccine against Infectious Bursal Disease and Marek’s Disease.
Levende svækket aviær infektiøs bronchitis virus, stamme D388: 104.0 - 105.5 EID50/dosis
Live attenuated avian infectious bronchitis virus, strain D388: 104.0 – 105.5 EID50/dose
Levende svækket aviær infektiøs bronchitis virus, stamme D388: 104.0 - 105.5 EID501
Live attenuated avian infectious bronchitis virus, strain D388: 104.0 – 105.5 EID501
Levende vaccine mod infektion i de øvre luftveje hos katte forårsaget af Bordetella bronchiseptica.
Live vaccine against feline upper respiratory tract disease caused by Bordetella bronchiseptica.
Levende vaccine mod mæslinger, fåresyge, røde hunde og skoldkopper
Measles, mumps, rubella and varicella vaccine (live)
Levende vacciner bør derfor ikke gives sideløbende med Ilaris, medmindre fordelene tydeligt opvejer risici.
Therefore, live vaccines should not be given concurrently with Ilaris unless the benefits clearly outweigh the risks.
Levende vacciner bør ikke gives samtidig med Inflectra (se pkt.
It is recommended that live vaccines not be given concurrently with Inflectra.
Levende vacciner bør ikke gives samtidigmed Remsima.
It is recommended that live vaccines not be given concurrently with Remsima.
Levende vacciner bør ikke gives sideløbende med Cosentyx.
Live vaccines should not be given concurrently with Cosentyx.
Levende vacciner: det anbefales, at du undgår at blive vaccineret med en type vacciner, der kaldes ”levende vacciner”, mens du bliver behandlet med Ilaris.
Live vaccines: you are advised to avoid being vaccinated with a type of vaccine called a live vaccine while being treated with Ilaris.
Levende vHVT013-69 rekombinant virus, min. .....................................................
Live vHVT013-69 recombinant virus, at least .......................................................
Levende vHVT013-69 rekombinant virus, min. .......................................................
Live vHVT013-69 recombinant virus, at least .........................................................
Levende vævs- ækvivalent
Living tissue equivalent
Levende,
Live attenuated
Levende,
Live-attenuated
Levende, fortyndet Aujeszkys sygdomsvirus
Live attenuated Aujeszky’s Disease Virus
Levende, fortyndet Aujeszkys sygdomsvirus, stamme NIA3-783: 105.2 CCID50* pr. dosis.
Live attenuated Aujeszky’s Disease
Levende, ikke-patogen vaccine til reduktion af udskillelse i fæces og kolonisering af tarmen med F4- positive enterotoksigene Escherichia coli hos svin.
Live non-pathogenic vaccine to reduce diarrhoea, faecal shedding and intestinal colonization associated with F4-positive enterotoxigenic Escherichia coli in pigs.
Levende, ikke-patogene Escherichia coli O8:K87......................1,3∙108 til 9,0∙108 CFU1/dosis
Live non-pathogenic Escherichia coli O8:K87............................1.3∙108 to 9.0∙108 CFU1/dose
Levende, ikke-patogene Escherichia coli O8:K871..............1,3∙108 til 9,0∙108 CFU2/dosis
Live non-pathogenic Escherichia coli O8:K871..............1.3∙108 to 9.0∙108 CFU2/dose
Levende, ikke-patogene Escherichia coli O8:K87: 1,3∙108 til 9,0∙108 CFU/dosis
Live non-pathogenic Escherichia coli O8:K87: 1.3∙108 to 9.0∙108 CFU/dose
Levende, rekombinant (CP7_E2alf)
Live recombinant (CP7-E2Alf)
Levende, rekombinant E2-gendeleteret bovin viral diarré virus indeholdende klassisk svinefeber E2 (CP7_E2alf) 104,8* til 106,5 TCID**50
Live Recombinant E2 gene deleted Bovine Viral Diarrhoea Virus containing Classical Swine Fever E2 (CP7_E2alf) 104.8* to 106.5 TCID**50
Levende, svækket Aujeszkys sygdomsvirus
Live attenuated Aujeszky’s disease virus
Levende, svækket rabiesvirus SAG2 stamme minimum 8 log 10 CCID50* /dosis
Live attenuated rabies virus, SAG2 strain 8 log10 - CCID50*/dose
Levende, svækket rabiesvirus SAG2 stamme minimum 8 log 10 CCID50* /dosis
Live attenuated rabies virus, SAG2 strain 8 log10 CCID50*/dose
Levende, svækket rabiesvirus, SAG2 stamme minimum 8 log 10 CCID50* /dosis
Live attenuated rabies virus, SAG2 strain 8 log10 - CCID50*/dose
Levende, svækket rabiesvirus, SAG2-stamme minimum 8 log 10 CCID50* /dosis
Live attenuated rabies virus, SAG2 strain minimum 8 log10 CCID50*/dose
Lever
Hepatic
Lever Nyre
NO ENTRY
Lever Nyre Muskler Fedt
Liver Kidney Muscle Fat
Lever og
Hepatobi
Lever og
Hepatobiliary
Lever og
Hepatobiliary disorders
Lever og
ystem
Lever og galde
Hepatobiliary disorders
Lever og galdeveje
54.6 a
Lever og galdeveje
Cholestasis, Abnormal liver function tests
Lever og galdeveje
Common
Lever og galdeveje
dizziness
Lever og galdeveje
Gastrointestinal and abdominal pain
Lever og galdeveje
Gastrointestinal disorders
Lever og galdeveje
General
Lever og galdeveje
General disorders and administration site conditions
Lever og galdeveje
Hepato biliary disorders
Lever og galdeveje
Hepato- biliary disorders
Lever og galdeveje
Hepato-biliary disorders
Lever og galdeveje
Hepato-biliary disorders:
Lever og galdeveje
Hepatobiliary
Lever og galdeveje
Hepatobiliary disorder
Lever og galdeveje
Hepatobiliary disorders
Lever og galdeveje
Hepatobiliary disordesrs
Lever og galdeveje
Hepatobiliary system
Lever og galdeveje
Hepatobiliary tract
Lever og galdeveje
Hepatobililary disorders
Lever og galdeveje
Hepatobilliary disorders
Lever og galdeveje
Immune system disorders
Lever og galdeveje
liver injury)11
Lever og galdeveje
Metabolism and nutrition disorders
Lever og galdeveje
Pancreatitis Hepatobiliary disorders
Lever og galdeveje
Psychiatric disorders
Lever og galdeveje
Renal and urinary disorders
Lever og galdeveje
Reproductive system and breast disorders
Lever og galdeveje
Respiratory, thoracic and mediastinal disorders
Lever og galdeveje
Skin and subcutaneous tissue disorders
Lever og galdeveje
system disorders
Lever og galdeveje
Uncommon
Lever og galdeveje
Very Common
Lever og galdeveje *
Hepato-biliary disorders
Lever og galdeveje Almindelig Unormal leverfunktionstest (herunder øget transaminase)
Hepatobiliary disorders Common Liver function test abnormal (including transaminases increased)
Lever og galdeveje Hyppighed ikke fastslået
Hepatobiliary disorders
Lever og galdeveje*
Hepatobiliary disorders
Lever og galdeveje:
Hepato-biliary disorders
Lever og galdeveje:
Hepato-biliary disorders :
Lever og galdeveje:
Hepato-biliary disorders:
Lever og galdeveje:
Hepatobiliary disorders
Lever og galdeveje:
Hepatobiliary disorders:
Lever og galdeveje: almindelig: gulsot ikke almindelig: hepatitis, cholelithiasisa, kolestasea sjælden: hepatosplenomegali, cholecystitisa
Hepatobiliary disorders: common: jaundice; uncommon: hepatitis, cholelithiasisa, cholestasisa; rare: hepatosplenomegaly, cholecystitisa
Lever og galdeveje: Ikke almindelig Ikke kendt:
Hepatobiliary disorders: Uncommon: Not known:
Lever og galdeveje: Ikke almindelig: Ikke kendt:
Hepatobiliary disorders: Uncommon: Not known:
Lever og galdeveje: Ikke kendt: Gulsot (intrahepatisk kolestatisk gulsot)
Hepatobiliary disorders: Not known: jaundice (intrahepatic cholestatic jaundice)
Lever og galdeveje: Ikke kendt: Hepatitis, abnorm leverfunktion
Hepatobiliary disorders: Not known: hepatitis, abnormal liver function
Lever og galdeveje: Kolestase, hepatitis (herunder hepatocellulær skade) (i de samlede fase III-studier var disse bivirkninger sjældne (≥ 1/10.000 til < 1/1.000)).
Hepatobiliary disorders: Cholestasis, Hepatitis (incl. hepatocellular injury) (In the pooled phase III trials, these events were rare (≥ 1/10,000 to < 1/1,000)).
lever- eller nyreproblemer
liver or kidney problems
lever- eller nyreproblemer
liver or kidney problems,
Lever- eller nyreproblemer.
Liver or kidney problems
Lever- eller nyresygdom
Liver or kidney disease
Lever- en galaandoeningen
Hepato-biliary disorders
Lever- og galdeveje
Hepato-biliary disorders
Lever- og galdeveje
Hepatobiliary disorders
Lever- og galdeveje:
Hepatobiliary disorders:
Lever- og galdevejshæ ndelser
Hepatobiliary events
Lever- og galdevejshændelser
Hepatobiliary events
Lever- og lungetoksicitet relateret til tidligere anvendelse af amiodaron.
Liver and lung toxicity related to the previous use of amiodarone.
Lever- tumorbyrde
Liver tumour burden
Lever.
Liver disorders.
Lever1
Liver1